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ture. We assumed re-intervention and septicaemia rates of ecAVG were equivalent 
to standard AVGs. Resource use was based on hospital practice and unit costs from 
published National Health Service datasets. Results: Over a 6 month period, total 
treatment costs per patient were £5,882 in the TCVC strategy and £4,954 in the 
ecAVG strategy, delivering potential savings of £927 per patient. Although ecAVG’s 
had higher procedure and re-intervention costs reflecting longer procedure time 
and device costs (£3,014 vs £1,836), these were offset by significant reductions in 
septicaemia treatment costs (£1,322 vs £2,176) and in-patient waiting time bed costs 
(£619 vs £1,870). ConClusions: Adopting ecAVG’s as an alternative to TCVCs can 
potentially deliver cost savings in this hospital. The two treatment strategies will 
now be assessed in a RCT.
PUK9
Early Timing Of ThE UsE Of ParicalciTOl fOr ThE TrEaTmEnT Of 
sEcOndary hyPErParaThyrOidism (shPT) in chrOnic KidnEy PaTiEnTs 
(cKd): a BUdgET imPacT analysis (Bi)
Lorenzoni V., Pierotti F., Turchetti G.
Scuola Superiore Sant’Anna, Pisa, Italy
objeCtives: Budget impact (BIM) analysis of the use of paricalcitol versus standard 
of care (SOC) for the treatment of secondary hyperparathyroidism (SHPT) in chronic 
kidney disease (CKD) considering paricalcitol treatment start in the pre-dialysis 
phase. Methods: Effects and costs deriving from the use of paracalcitol versus 
SOC for treatment of SHPT in CKD patients were simulated using a Markov models 
contemplating the natural history of CKD and introducing the use of parcalcitol 
treatment from the early stage of kidney disease (CKD3) versus SOC considering 
the use of comparator only from the dialysis stage. A 5-years horizon and the Italian 
NHS perspective were used. Epidemiologic and clinical data were derived from 
literature and other assumptions were discussed with clinicians. Both national 
tariffs and costs from literature were used upon availability and referred to 2012. 
One-way sensitivity analyses for model inputs were conducted. Costs and effects 
were discounted at 3% annum. Results: The use of paricalcitol for the treatment 
of SHPT was cost-saving for the Italian NHS even starting therapy in the early stage 
of CKD. In a hypothetical cohort of 1,000 patients per treatment group, the overall 
direct health costs were 10,181,627 Euro for paricalcitol and 10,816,812 Euro for SOC. 
Both drug-related and others direct costs were lower for paricalcitol resulting in 
an overall cost-saving of 1,256 Euro per-patient and stemming from a per-patient 
increase of drug-related costs of 5,126 Euro and a saving of the others direct costs 
of 6,382 Euro. ConClusions: Timing paricalcitol treatment from the early stage 
of CKD could induce a cost-saving for the NHS. Moreover, despite the high acquisi-
tion costs for paricalcitol, benefits resulting from an early treatment of SHPT could 
determine a decrease of the others direct costs exceeding the burden of drug costs.
PUK10
PharmacOEcOnOmic assEssmEnT Of TrEaTmEnT WiTh a lOW PrOTEin 
diET and KETOanalOgUEs Of EssEnTial aminOacids fOr PrEdialysis 
PaTiEnTs in rUssian fEdEraTiOn
Serpik V.G., Yagudina R., Kulikov A.
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
bACkgRound: Clinical studies have shown that treatment of chronic kidney dis-
ease patients at predialysis stage (predialysis) with a low protein diet (LPD) and 
ketoanalogues of essential aminoacids (ketoanalogues) provides clinical and eco-
nomic benefits. Then, it’s actual to define pharmacoeconomic effects of using LPD 
and ketoanalogues in predialysis patients in Russian Federation (RF). objeCtives: 
To provide pharmacoeconomic assessment of LPD and ketoanalogues supply of 
predialysis patients in RF. Methods: Decision tree modelling approach, cost-utility 
(CUA) and budget impact analyses (BIA) were performed. Direct costs (ketoana-
logues, erythropoietin, hemodialysis, peritoneal dialysis, etc.) were considered. Two 
patients groups were compared in the model: ketoanalogues and LPD was adminis-
trated for the first arm in predialysis stage, while second arm started in the model of 
dialysis patients. Results of retrospective efficacy analysis state, that administration 
of keto-analogues and LPD delays start of dialysis at least for one year. State utility 
approach was used for cost-utility analysis. Time horizon of the model was up to 5 
years. NHS prices and Sechenov University hospitals price lists were used. Results: 
The first year annual costs were $38511 per patient for the patients group on dialysis 
and $13763 for the group of ketoanalogues. The results of BIA have shown, that total 
cost-saving per patient in the group of ketoanalogues and LPD over 5-year period 
was $21812 compared with the dialysis group. Cost-utility ratio (CUR) for the keto-
analogues and LPD group varies from $15316 per QALY for the first year to $34673 
per QALY over five years, while in the dialysis group CUR ranged from $50051 per 
QALY in the first year to $45819 per QALY over five years. ConClusions: CUA have 
shown that treatment of predialysis patients with ketoanalogues and LPD in RF is a 
preferable technology and provides cost-saving of $21812 over five years per patient.
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cOmParaTivE cOsT-analysis Of six anTichOlinErgics fOr ThE 
TrEaTmEnT Of OvEracTivE BladdEr and incOnTinEncE in PaTiEnTs 40 
yEars Or OldEr in gErmany
Felder S.1, Grabe K2, Mayrhofer T.3
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objeCtives: Comparing the costs of Darifenacin, Oxybutynin, Propiverine, 
Solifenacin, Tolterodine, and Trospium chloride for the treatment of overactive blad-
der (OAB) and incontinence in patients 40 years of age or older in Germany. dAtA 
And Methods: Costs are assessed from a (public) health insurance perspective. 
The study is based on a unique sickness fund dataset of 2.9 million insured per-
sons which includes records on out- and inpatient care, pharmaceuticals, adjuvant 
therapies, and medical aids for 2009. 21,302 persons aged 40 years or older received 
anticholinergics and were classified as OAB patients. Of these OAB patients, 3,846 
also suffered from incontinence. Multiple linear regression models were performed, 
PUK6
imPacT Of arThriTis and OThEr cOmOrBidiTiEs On incidEncE Of 
Urinary incOnTinEncE: a casE cOnTrOl sTUdy
Potukuchi P.K.1, Johnson J.T.1, Martin B.1, Hutchison L.C.2, Bursac Z.1, Said Q.1
1University of Arkansas for Medical Sciences, Little Rock, AR, USA, 2University of Arkansas for 
Medical Sciences, Little Rock, AR
objeCtives: Urinary Incontinence (UI) is associated with several chronic health 
conditions including arthritis. Literature suggests that arthritis may modify the 
association between chronic conditions and UI. Little is known about this interaction 
of arthritis with other chronic diseases and their impact on UI. This study exam-
ined these associations. Methods: This was a retrospective case-control study of 
a 10% random sample of IMS Life Link data from 2001-2011. Subjects were > = 18 
years of age and continuously enrolled 18 months pre, and 12 months post their 
first index diagnosis. UI cases had at least two outpatient or one inpatient and one 
outpatient claim at least 7 days apart, or one pharmacy claim for a UI drug. Controls 
without UI had the same eligibility criteria as cases and were matched with cases 
3:1 on age, gender and region. Comorbidities are observed in the 12-month pre-
index period after leaving 6 months buffer time immediately before index diagno-
sis. Conditional logistic regression (CLR) adjusted for health system variables and 
other co-morbidities was used to investigate the effect of the interaction between 
arthritis and other comorbidities on UI. Results: There were 24,499 cases, and 
73,497 controls with a mean age of 58.29 years and 69.8% females. Forty percent of 
cases and 24.8% of controls had arthritis in their pre index period. Arthritis alone 
was significantly associated with UI alone (aOR = 1.87, p< 0.0001), multiple Sclerosis 
(MS) alone (aOR = 4.25, p< 0.0001) and cardiovascular diseases (CVD) alone (aOR = 
1.32, p< 0.0001). However, the interaction of arthritis and MS (aOR = 7.48, p< 0.0001), 
and arthritis and CVD (aOR = 2.10, p< 0.0001) increased considerably the odds of 
developing UI. ConClusions: Compared to arthritis or chronic conditions alone, 
the combination of arthritis with other chronic conditions significantly increases 
the risk of having UI.
PUK7
lEngTh Of sTay and mOrTaliTy in hyPErPhOsPhaTEmia PaTiEnTs 
adminisTErEd PhOsPhaTE BindErs cOmParEd WiTh maTchEd cOnTrOls
Belk K.W., Craver C.W.
MedAssets, Charlotte, NC, USA
objeCtives: Hyperphosphatemia, an electrolyte disorder characterized by elevated 
levels of phosphate in the blood, is a risk factor for chronic kidney disease (CKD) 
and associated with increased risk of mortality. In addition to dietary changes 
phosphate binders (PB) may be administered to hyperphosphatemia patients to 
reduce phosphate levels. The objective of this study is to evaluate the impact of 
PB on CKD patients with hyperphosphatemia. Methods: A retrospective, cross-
sectional analysis was conducted on 70,728 inpatient discharges in the MedAssets 
health system data diagnosed with CKD and hyperphosphatemia for 2009 through 
2013. Cohorts of patients with and without PB were matched on age, sex, principal 
diagnosis, hospital bed size, region, and teaching status using a propensity score 
and Greedy matching algorithm. In-hospital mortality and length of stay (LOS) were 
compared between cohorts using multivariate logistic and negative binomial regres-
sion models, respectively, controlling for Deyo-Charlson comorbidity score, compli-
cations, and procedures. Results: Of patients diagnosed with hyperphosphatemia 
approximately 46% were administered PB during their stay. Matching resulted in 
11432 patients in each cohort with a mean age of 61 and proportionately more 
males (54%) than females (46%). Patients receiving PB had higher Deyo-Charlson 
scores (5.70 vs. 5.46, p< .0001) and higher rates of end-stage renal disease (74.6% vs 
44.1%, p< .0001) and hemodialysis (65.4% vs 35.4%, p< .0001). Patients without PB had 
higher rates of acute kidney failure (48.0% vs 33.7%, p< .0001) and transplants (6.8% 
vs 2.0%, p< .0001). After adjusting for complications and comorbidities phosphate 
binder use was associated with 7.7% more inpatient days (IRR = 1.077, p< .0001) and 
a 28% mortality reduction (OR= 0.718, p< .0001). ConClusions: After controlling 
for other variables, CKD patients with hyperphosphatemia receiving PB had lower 
risk of in-hospital mortality and longer LOS compared to patients without a PB. 
Further studies should assess post-hospitalization outcomes as well as variation 
among types of PB.
Urinary/KidnEy disOrdErs – cost studies
PUK8
Early cannUlaTiOn arTEriOvEnOUs vascUlar grafTs fOr 
haEmOdialysis: a cOsT-saving alTErnaTivE TO TUnnElEd cEnTral 
vEnOUs caThETErs? an EsTimaTEd BUdgET imPacT analysis in a singlE-
cEnTrE
Iqbal K.1, Aitken E.2, Thompson P.2, Kingsmore D.2
1WL Gore & Associates Ltd, Livingstone, UK, 2Western Infirmary, Glasgow, UK
objeCtives: Tunnelled central venous catheters (TCVCs) are frequently used for 
patients requiring urgent vascular access for haemodialysis (HD), whilst they await 
definitive access creation, primarily arteriovenous fistula (AVF). TCVCs are associ-
ated with significant complications notably higher rates of septicaemia which are 
costly to treat. Early cannulation arteriovenous grafts (ecAVGs) are a new alternative 
providing vascular access for HD within 24 hours post implantation. We estimated 
the potential budget impact in a single hospital of replacing TCVCs with ecAVG’s 
for clinically suitable patients while they awaited a functioning AVF. The analysis 
was used to understand the potential financial implications of adopting ecAVGs 
and to inform the decision to conduct a Randomised Controlled Trial (RCT) to study 
the above hypothesis. Methods: A budget impact model was used to estimate 
the total costs to the hospital of the two treatment strategies. Costs of procedures, 
re-interventions and septicaemia were included. Clinical inputs including referral 
delays for treatment and patient acceptability of ecAVG’s, were taken from a 6 month 
observational study conducted at the hospital, internal audits and published litera-
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objeCtives: To analyze the cost of illness in the management of anemia among 
chronic kidney disease (CKD) patients on hemodialysis Methods: Prospective 
observational study for a period 7 months was conducted after the approval of the 
protocol by the Ethics Committee. The patients on hemodialysis of both sexes aged 
between 18-75 years were enrolled in the management of anemia with erythropoi-
etin (EPO). The data relating to the cost and the number of units for EPO, Iron and 
Vitamin supplements were recorded and computed on weekly basis. Hemoglobin 
levels were recorded every month. The average cost incurred was calculated for 7 
months. Results: The number of subjects included in the study was 62 out of 96 
patients. The total number of EPO administered for 7 months was computed by 
adding all the doses for 7 months. On an average, each subject was administered 
27.44 of EPO doses equivalent to 113001.35 IU. The Iron supplements and vitamins 
constituted 15.54 doses and 32.6 doses respectively. The response of above-men-
tioned treatment reflected in raise in 8.67 g/dl hemoglobin levels per patient per 7 
months. The cost of EPO for doses administered was 111859.92 INR (1864.32 USD), 
Iron supplements 5594.4 INR (93.24 USD), Vitamin supplements 1587.83 INR (26.46 
USD). In addition, the laboratory charges for the measurement of hemoglobin levels 
were 325 INR (5.41 USD) per patient per 7 months. ConClusions: Study reveals 
64.58% of patients were economically sound to undergo the treatment with EPO. 
Eighteen patients were covered by Employees’ State Insurance and 2 patients sup-
ported by their employers on reimbursement basis and the remaining 40 patients 
borne the expenses by themselves. The study revealed that the average cost in the 
management of anemia among chronic kidney disease patients on hemodialysis 
per patient per 7 months was 119367.15 INR (1989.45 USD).
PUK15
ThE sOcial cOsT Of chrOnic KidnEy disEasE in iTaly
Bellelli S., Turchetti G.
Scuola Superiore Sant’Anna, Pisa, Italy
objeCtives: Chronic kidney disease (CKD) represents a major public health concern 
with a great economic burden. The aim of the study is to estimate the mean annual 
social cost of a patient with CKD by stage (IV and V pre-dialyses) and cost component 
in Italy. Methods: The cross sectional study included all adult outpatients that 
were in charge of the 14 main Hospital Centers in the Tuscany Region during 7 week. 
Direct medical costs have been estimated using tariff for laboratory test, diagnostic 
exams, visits and hospitalization and price for drugs. Non medical costs included 
the cost of diet, patients and caregivers travel expenses, formal and informal care. 
The loss of productivity of patients and caregivers have been estimated as indirect 
costs using the human capital approach. Costs are expressed as mean (± standard 
deviation) in Euro 2012. Results: 279 patients in stage IV and 205 patients in stage 
V have been enrolled. The estimated mean annual social cost of a patient with 
CKD were € 9,185 (± € 6,319) for stage IV and € 10,766 (± € 8,314) for stage V (p< 0,05). 
Direct medical costs were higher in stage V as compared to stage IV (€ 5,049 ± € 
4,017 versus € 3,840 ± € 4,042, p< 0,05). Direct non medical costs and indirect costs 
accounted respectively for 32% and 26% of the total social cost for CKD stage IV and 
for 26% and 27% of the total social cost for CKD stage V. In Italy the overall annual 
social cost of CKD stage IV and V was € 2,158,903,299 representing the 0.14% of the 
GDP. ConClusions: Direct non medical costs and indirect costs represent the main 
component of the social cost of CKD. Patients, their families and the productivity 
system mainly sustain the burden of the disease.
PUK16
mEdical ExPEnsE BUrdEn Of EmPlOyEE’s hEalTh insUrancE 
ParTiciPanTs WiTh chrOnic rEnal failUrE in china
Xiong X.1, Lin J.1, Meng W.1, Mao Y.2
1China Health Insurance Research Association, Beijing, China, 2Xi’an Jiaotong University, Xi’an, 
Shannxi Provice, China
objeCtives: To investigate the employee’s health insurance payment policy 
for stage-5 chronic renal failure patients treated with dialysis as well as stage1-4 
patients, analyze payment levels of the insurance and out-of-pocket medical 
expense. Methods: This study involved 8809 stage-5 chronic renal failure cases 
treated with dialysis and 14472 stage1-4 cases in 6 provincial capital & vice-provincial 
cities (Shenyang, Nanjing, Qingdao, Zhengzhou, Chengdu, Urumchi).The actual claim 
data of medical expenses and medical care utilization from 2008 to 2010 were col-
lected. Descriptive analysis was applied to the data. The employee’s health insurance 
payment policies of the 6 cities were reviewed. Results: 1) All the cities provided 
both inpatient and outpatient medical expense payment for stage-5 chronic renal 
failure with dialysis, but for stage1-4 only 3 cities provided both inpatient and outpa-
tient payment while the others did not pay for outpatient.2) The actual payment levels 
of inpatient expense for dialysis ranged from 70% to 80%, and those of outpatient 
ranged from 70% to 90% in various cities. The out-of-pocket expense for inpatient 
and outpatient were US$839 and US$829,respectively. 3) In the 3 cities which pro-
vided both inpatient and outpatient payment for stage1-4 chronic renal failure, the 
actual payment levels for inpatient ranged from 64% to 77% and those of outpatient 
ranged from 61% to 75% . The out-of-pocket expense for inpatient and outpatient 
reached US$510 and US$464, respectively. ConClusions: Generally,health insur-
ance for employees eased the economic burden of stage-5 patients with dialysis and 
made out-of-pocket expense acceptable. Provision of outpatient payment for stage1-4 
patients is necessary in lowering the economic burden and meeting the outpatient 
service demand of the patients. Therefore,the employee’s health insurance should 
strengthen medical service monitoring for dialysis,handle the catastrophic medical 
expense risk of stage-5 patients with extremely high medical expenses and provide 
outpatient payment for stage1-4 patients.
PUK17
cOsT Of illnEss analysis Of dialysis in diffErEnT rEgiOns Of rUssia
Kulikov A.1, Abdrashitova G.T.2, Serpik V.G.2
1First Moscow State Medical University named after I. M. Sechenov, Moscow, Russia, 2I.M. 
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controlling for age and gender effects on costs. Moreover, a propensity score match-
ing analysis was used to test for robustness of the results. Results: OAB patients 
caused additional annual costs of € 772 compared to non-OAB patients. Patients 
treated with Oxybutynin had the lowest additional costs (€ 660) while patients 
treated with Tolterodine yielded the highest additional costs (€ 1,049). In the special 
case of incontinence, patients treated with Solifenacin incurred the lowest addi-
tional costs (€ 1,242) and patients treated with Tolterodine the highest (€ 1,835). 
The lower treatment costs for Solifenacin are mainly driven by lower spending on 
medical aids, especially due to lower pad usage. All results are highly significant (p 
< 0.01) and propensity score matching produced similar findings. ConClusions: 
This study compares the annual cost of six anticholinergics for the treatment of 
OAB and incontinence in patients 40 years of age or older in Germany. OAB patients 
treated with Oxybutynin and incontinent patients treated with Solifenacin have 
shown the lowest additional cost. For both patient groups Tolterodine is associated 
with the highest additional cost of treatment.
PUK12
rEal-WOrld dOsE EqUivalEncy and cOsT cOmParisOns Of 
cOnvErsiOns BETWEEn sEvElamEr hydrOchlOridE/carBOnaTE and 
lanThanUm carBOnaTE mOnOThEraPiEs
Keith M.S.1, Sibbel S.P.2, Copley J.B.1, Wilson R.J.3, Brunelli S.M.2
1Shire Pharmaceuticals, Wayne, PA, USA, 2DaVita Clinical Research, Minneapolis, MN, USA, 
3Spica Consultants, Marlborough, UK
objeCtives: To determine the real-world dose equivalency of sevelamer hydro-
chloride/carbonate (SH/C) and lanthanum carbonate (LC) monotherapies, and 
compare the drug costs associated with various dosages of SH/C versus conver-
sion to LC. Methods: Data were evaluated retrospectively for patients receiving 
hemodialysis in the US, who converted in either direction between SH/C and LC 
monotherapies, yet had similar phosphate (P) levels over the observation period. 
The study comprised a 90-day pre-conversion period followed by a 90-day post-
conversion period. Serum P and daily P binder doses were assessed across six 30-day 
periods. Primary comparisons were based on data from the last month of each 
treatment period to allow for clinical equilibration. Drug cost assessments were 
based on prescription fills and REDBOOK pricing (Sept 2013). Results: A total of 
303 patients met study criteria: 128 converted from SH/C (mean dose ~8200 mg/day) 
to LC (~3400 mg/day) and 175 converted from LC (~3800 mg/day) to SH/C (~8600 mg/
day). In the post-conversion, serum P ranged from 5.99±1.64 mg/dL to 6.43±1.87 mg/
dL in patients converting from SH/C to LC, and from 6.18±1.68 mg/dL to 6.51±1.92 
mg/dL in those converting from LC to SH/C. For combined patient cohorts, the overall 
dose equivalency of SH/C:LC was 2.27. Mean P binder costs were $1080±491/patient/
month with SH/C and $1006±513 with LC. Mean cost differences between pre- and 
post-conversion phases, in either direction, were –$74.20/patient/month (95%CI 
–141.80, –6.63; p< 0.05) in favor of LC. Cost differences between LC and SH/C were 
greatest (–$359; 95%CI –485, –260; p< 0.001) in favor of LC, in patients receiving > 7200 
mg SH/C daily (50.7% of patients). ConClusions: Patients who converted between 
LC and SH/C monotherapies in either direction maintained similar P levels in both 
conversion phases. LC was 2.27 times as potent as SH/C on an mg-to-mg basis and 
was associated with significantly lower P binder costs.
PUK13
hEalTh carE cOsTs amOng PaTiEnTs WhO cOnTinUE ThEraPy Or sWiTch 
anTimUscarinic agEnTs fOr OvEracTivE BladdEr
Ivanova J.1, Hayes-Larson E.1, Sorg R.A.1, Birnbaum H.G.2, Fitzmartin J.3, Berner T.3
1Analysis Group, Inc., New York, NY, USA, 2Analysis Group, Inc., Boston, MA, USA, 3Astellas 
Scientific and Medical Affairs, Inc., Northbrook, IL, USA
objeCtives: To compare health care costs among patients who continued ther-
apy or switched antimuscarinic agents for overactive bladder (OAB). Methods: 
Patients initiating antimuscarinic therapy from 1/1/2007-3/31/2012 diagnosed with 
OAB were identified from a large claims database of privately insured patients. 
Patients were required to have no antimuscarinic claims in the 12 months before 
their antimuscarinic initiation (baseline period), continuous coverage for ≥ 12 
months before and after antimuscarinic initiation, and age 18-64 years. Based on 
claims in the 6 months after antimuscarinic initiation, patients who continued 
index antimuscarinic therapy were categorized as persisters (n= 3,197), and patients 
with a claim for a non-index antimuscarinic agent (without a gap > 60 days after 
the end of index antimuscarinic treatment) were categorized as switchers (n= 828). 
The study index date was defined as the date of switching from index antimus-
carinic for switchers and a randomly assigned date (matching the distribution of 
time from initiation to switching) for persisters. All-cause and OAB-related costs 
(i.e., reimbursements to providers for medical and pharmacy claims) in the month 
prior to and 6 months after the index date were compared using generalized lin-
ear models controlling for baseline characteristics and baseline costs. Results: 
Persisters compared with switchers were older and had lower baseline costs. After 
controlling for baseline characteristics and costs, all-cause and OAB-related costs 
in both the month before and 6 months after the index date were significantly 
lower among persisters than switchers (1 month before: all-cause $1,222 vs. $1,759, 
OAB-related $142 vs. $170; 6 months after: all-cause $7,017 vs. $8,806, OAB-related 
$642 vs. $797; all p< 0.0001). ConClusions: All-cause and OAB-related costs in the 
period immediately before and after switching were higher among patients who 
switched antimuscarinic therapies compared with patients who persisted on their 
index antimuscarinic therapy.
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